Joel Greenberger M.D. is an established Radiation Biologist and Radiation Oncologist.He has uninterrupted NIH funding since 1977 and also DoD and NASA funding for his research on the radiobiology of hematopoietic, gastrointestinal and lung stem cells.Since 2005 has been the Principal Investigator on a U19 NIAID Center for Medical Countermeasures against radiation( for 15 years )and then U01 grants focused on discovery and elucidation of the mechanism of radiation protection and mitigation by both systemic delivery of small molecules and gavage of genetically engineered lactobacillus reuteri that is releasing IL-22 or IFnB. He was Chairman of Radiation Oncology at Pitt from 1993-2022 and treated primarily esophagus and lung cancer. His Interest in Space Radiation focuses on defining the spectrum of acute and chronic injury caused by sporadic solar proton events, galactic cosmic irradiation, neutrons and gamma irradiation and on developing dietary and pharmaceutical countermeasures.Also interest in the polypharmacy of astronaut-drugs to mitigatate threats during space travel including: physical and neuropsychiatric stress, weightlessness, isolation, and both acute and late effects of space radiation.
